On Thursday, H.C. Wainwright adjusted the price target for Adaptimmune Therapeutics plc (NASDAQ:ADAP) to $3.50 from the previous $4.00, while reaffirming a Buy rating on the stock. This change follows the company's third-quarter financial results, which were disclosed on Wednesday.
Adaptimmune reported a third-quarter total revenue of $40.9 million, which notably surpassed the consensus estimate of $19.0 million. The company's net loss for the quarter was $0.01 per share, aligning with consensus estimates. The significant revenue increase is primarily attributed to the accelerated recognition of deferred revenues following the conclusion of their collaboration with Genentech.
The analyst from H.C. Wainwright has updated their financial model for Adaptimmune to reflect the recent financial results. Looking ahead to the entirety of 2024, the firm projects that Adaptimmune will generate revenues of $192 million and record a net loss of $0.02 per share.
The revised price target of $3.50 per American Depositary Share (ADS) over the next 12 months represents a decrease from the previous target but maintains an optimistic outlook on the company's stock, as indicated by the continued Buy rating.
In other recent news, Adaptimmune Therapeutics PLC has been notified by Nasdaq about a potential delisting due to its American Depositary Shares (ADS) trading below the $1.00 threshold for 30 consecutive business days. Adaptimmune has until April 30, 2025, to regain compliance, which would require the closing bid price of its ADSs to reach $1.00 or more per share for at least ten consecutive business days. The biotechnology firm has expressed its intention to closely monitor the bid price of its ADSs and evaluate possible actions to regain compliance with Nasdaq's listing standard.
In parallel, Adaptimmune has finalized its settlement with Genentech Inc., resolving all disputes related to their previous collaboration. The settlement includes a payment of $12.5 million to Adaptimmune, marking the end of their collaborative chapter.
Another recent development is the launch of Tecelra, Adaptimmune's first engineered cell therapy product for synovial sarcoma. The company reported a robust financial position, with $215 million in total liquidity, and plans to activate 6 to 10 authorized treatment centers for Tecelra. It is also progressing with its SURPASS-3 trial for lete-cel and collaborating with Galapagos (NASDAQ:GLPG) for a proof-of-concept trial in head and neck cancer. Adaptimmune anticipates consistent operating expenses in line with the first half of 2024.
InvestingPro Insights
Recent InvestingPro data offers additional context to Adaptimmune Therapeutics' financial landscape. The company's market capitalization stands at $197.08 million, with a revenue of $141.46 million for the last twelve months as of Q2 2024. Notably, Adaptimmune has experienced substantial revenue growth, with a 99.9% increase over the same period.
Two key InvestingPro Tips shed light on the company's financial position. Firstly, Adaptimmune "holds more cash than debt on its balance sheet," which aligns with the analyst's optimistic outlook despite the lowered price target. Secondly, the company is "quickly burning through cash," a factor that investors should consider alongside the projected revenues and net loss for 2024.
These insights are part of 11 additional tips available on InvestingPro, offering a more comprehensive analysis of Adaptimmune's financial health and market position. For investors seeking a deeper understanding of ADAP's potential, exploring the full range of InvestingPro Tips could provide valuable guidance in light of the recent analyst update.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.